Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9044605 | 0.82 | OPRK1 (0.36) | OPRK1KCNH2ALDH1A1HTTFDPS | |
| Hydrochloric Acid SCHEMBL5657421 | 0.79 | OPRK1 (0.40) | OPRK1HTT | |
| SCHEMBL2647561 | 0.78 | — | — | |
| SCHEMBL8026054 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL1187702 | 0.76 | KMT2A (0.42) | KCNH2ALDH1A1HTT | |
| SCHEMBL17865370 | 0.74 | KCNH2 (0.41) | KCNH2ALDH1A1HTTFDPS | |
| SCHEMBL23758318 | 0.72 | OPRK1 (0.35) | OPRK1FDPS | |
| SCHEMBL7484112 | 0.72 | FDPS (0.32) | KCNH2FDPS | |
| SCHEMBL24697664 | 0.72 | OPRK1 (0.35) | OPRK1FDPS | |
| SCHEMBL6521463 | 0.72 | FDPS (0.54) | OPRK1KCNH2ALDH1A1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115124512-A | Cyclic amine derivative and medical use thereof | 东丽株式会社 | 2022-09-30 | — | — | CN | disclosed |
| CN-112739343-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-04-30 | — | — | CN | disclosed |
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | OPRK1 305/4885KCNH2 29/4885ALDH1A1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.